Juliana Campos

Portugal

Freelance Writer at Rare Disease Advisor

PhD candidate in Biochemistry 🎓 fuelled by curiosity and passionate about learning. Always seeking to challenge myself. Now stepping into data science!

Articles

Study Ranks Zanubrutinib Best in Class for High-Risk CLL

1 week ago | rarediseaseadvisor.com | Juliana Campos

Zanubrutinib is the most effective Bruton tyrosine kinase inhibitor (BTKi) for patients with high-risk relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), according to results of a new study published in Blood Advances. “To our knowledge, this is the first indirect treatment comparison to assess the comparative efficacy of BTKi therapies for patients with CLL considered to be at high risk based on the presence of specific genetic mutations,” the study’s authors said.
Zebrafish Model Mimics Hemophilia B for Drug Discovery

1 week ago | rarediseaseadvisor.com | Juliana Campos

Researchers have successfully developed a zebrafish model of hemophilia B, according to results published in Blood Coagulation & Fibrinolysis. The study showed that CRISPR-mediated knockout of f9a in zebrafish eliminates F9a expression at both the mRNA and protein levels. This resulted in a mild bleeding phenotype that mirrors the clinical features of hemophilia B.
ECIL Committee Updates Antifungal Prophylaxis Guidelines for MDS, ALL, and CLL

1 week ago | rarediseaseadvisor.com | Juliana Campos

The European Conference on Infections in Leukemia (ECIL) committee has recently updated its guidelines on antifungal prophylaxis for both pediatric and adult patients with hematologic malignancies, including myelodysplastic syndromes (MDS), acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL).
New Oral Drug Shows Promise in Slowing IPF Progression

1 week ago | rarediseaseadvisor.com | Juliana Campos

Admilparant (BMS-986278), an oral lysophosphatidic acid receptor 1 (LPA1) antagonist, may help slow the progression of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), according to the results of a phase 2 study published in Chest. Patients with IPF receiving admilparant had a lower risk of disease progression over 26 weeks compared to those on placebo.
Test Your Knowledge About the Comorbidities of Achondroplasia

1 week ago | rarediseaseadvisor.com | Juliana Campos

Which of the statements below about the comorbidities of achondroplasia are correct? Select one of the options for each question, then submit your answers to see how well you scored and how other test takers voted. Read more about achondroplasia comorbidities.
Adult Care Transition Linked to Poorer Outcomes in SCD

2 weeks ago | rarediseaseadvisor.com | Juliana Campos

Transitioning from pediatric to adult care is associated with poorer health outcomes in patients with sickle cell disease (SCD), according to results from a study published in the Journal of Adolescent Health. In a cohort of young adults with SCD (age range, 18-23 years), those who remained under pediatric care had significantly fewer emergency department visits and hospital admissions compared with those who transitioned to adult care.
Noninvasive Prenatal Testing May Reduce Unnecessary Anti-D Immunoglobulin Use

2 weeks ago | rarediseaseadvisor.com | Juliana Campos

Noninvasive prenatal testing of fetal RhD status could reduce unnecessary anti-D immunoglobulin administration, according to results of a new study published in Scientific Reports. This approach has the potential to improve resource utilization and avoid unnecessary treatments, while still providing adequate care for those at risk for hemolytic disease of the fetus and newborn (HDFN).
Limitations Found in the Reuse of Limb-Lengthening Implants in Achondroplasia

2 weeks ago | rarediseaseadvisor.com | Juliana Campos

Important concerns are associated with the reuse of telescopic intramedullary nails (TIMNs) in limb-lengthening procedures for patients with achondroplasia, according to a study published in Revista Española de Cirugía Ortopédica y Traumatología. Experimental analysis of a femoral TIMN that had undergone lengthening procedures revealed chemical and mechanical damage to the titanium-aluminum-vanadium alloy (Ti6Al4V).
Case Report: Endoscopic Surgery Resolves Spinal Condition in Achondroplasia

2 weeks ago | rarediseaseadvisor.com | Juliana Campos

Doctors have successfully treated lumbar spinal stenosis (LSS) in a patient with achondroplasia using a minimally invasive endoscopic technique, according to a case report published in the European Spine Journal. The patient, a 33-year-old male with achondroplasia, presented with a 3-month history of low back pain and right leg radicular symptoms corresponding to the L5 nerve root distribution. Walking exacerbated these symptoms, while rest significantly relieved them.
Experts Discuss Best Practices for the Management of Indolent SM

2 weeks ago | rarediseaseadvisor.com | Juliana Campos

The German Society of Allergy (AeDA) has released a new position paper outlining best practices for the management of indolent systemic mastocytosis (ISM). In light of recent therapeutic advances and growing insights into disease mechanisms, the AeDA emphasized the importance of early diagnosis, individualized treatment strategies, and multidisciplinary care.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

X (formerly Twitter)

Followers: 24
Tweets: 43
DMs Open: No

Juliana Felgueiras @julianafelg

7 Jan 21

Check out the next Virtual Conference on Molecular Pathology

EACR @EACRnews

📢 NEW joint Virtual Conference on Molecular Pathology with OECI! This meeting, 23-24 March, will cover topics including: - Current views on Molecular Pathology - new technologies in onco-pathology To find out more about #eacrMolecularPathology, visit: https://t.co/GVXvHWB5my https://t.co/AASGsehiNz

Juliana Felgueiras @julianafelg

7 Jan 21

7 dias de 2021 e já assistimos ao maior ataque à democracia americana das últimas décadas. E achávamos nós que 2021 ia ser melhor! Ingénuos 🤦‍♀️

Juliana Felgueiras @julianafelg

17 Nov 20

Hope so!

Twitter User @user